In this prospective clinical imaging study the feasibility, safety and benefit of ssIA (compared to IV) administration of a PSMA-targeting radioligand was assessed, with the aim to provide quantitative evidence and modelled predictions for the potential of PSMA-based RLT for treatment of malignant brain tumours. This evidence concerns the gene FOLH1 and brain neoplasm.